What is Zinbryta?
Approved by the FDA in August 2016, Zinbryta (generic: daclizumab) is a disease-modifying therapy for adults with relapsing forms of multiple sclerosis (MS). It is an injectable drug intended to be taken every 4 weeks, that works by binding to immune cells (lymphocytes or white blood cells) and reducing the activity of cells that cause damage associated with multiple sclerosis. Zinbryta is manufactured and marketed in a joint partnership between between Biogen and Abbvie, Inc.
On March 2, 2018, Biogen and Abbvie announced that they were withdrawing Zinbryta from the global market after reports surfaced of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, in multiple sclerosis patients treated with the drug.
At least 12 cases of Zinbryta encephalitis have been reported worldwide, according to the FDA, and 3 of those cases were fatal. Zinbryta has also been linked to liver failure, serious skin reactions, and other side effects.
The FDA says it is working closely with Biogen and Abbvie “to help ensure a well-organized withdrawal from the market in the United States, and to ensure that healthcare professionals have the information they need to carefully transition their patients using Zinbryta to another treatment.”
Side Effects of Zinbryta
Serious side effects of Zinbryta may include:
- Liver failure
- Drug-induced hepatitis
- Inflammatory encephalitis
If You Are Taking Zinbryta
ls currently taking Zinbryta, you should not using it without talking to your doctor first. Your healthcare providers can help determine whether alternative treatment options are a good idea for you, and which ones are best. Current Zinbryta users should have their blood tested monthly to assess liver function, and for up to 6 months after their last dose, according to the Medication Guide.
Why Our Law Firm is Filing Individual Lawsuits Opposed to a Class Action
Although Schmidt & Clark, LLP, is a nationally recognized class action firm, our lawyers have decided against pursuing class action litigation over Zinbryta, and are only filing individual claims on behalf of individuals with the most severe injuries. It has been our experience that in these types of cases, class action lawsuits often result in “lowball” settlement agreements and higher attorney fees. At Schmidt & Clark, LLP, our goal is to maximize compensation for all of our clients, which is why we are only pursuing individual litigation on behalf of injured parties. Contact us today to learn more about your legal rights.
Do I Have a Zinbryta Class Action Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Zinbryta lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
Free Case Evaluation: Again, if you’ve been harmed by the side effects of a multiple sclerosis treatment, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.